A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

NCT06525636

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Kyowa Kirin Co., Ltd.
Enrollment	24 participants

Key Eligibility Criteria

Inclusion (22)

- Male or female patients aged 18 to 65 years inclusive at the time of signing the ICF.
- Body weight is at least 40 kg.
- Diagnosed with XLH (as documented by the investigator).
- Have a value of fasting serum phosphorus \< 2.5 mg/dL (0.81 mmol/L) at Screening.
- Have a value of renal TmP/GFR \< 2.5 mg/dL (0.81 mmol/L) at Screening.

... and 17 more (see full listing online)

Exclusion (36)

- For XLH patients previously treated with burosumab, use of burosumab within 7 months prior to ICF signature.
- Prior history of positive test for human immunodeficiency virus antibody, positive test for hepatitis B surface antigen, and/or hepatitis C virus antibody at Screening.
- History of hypersensitivity to any ingredient of any therapeutic monoclonal antibody.
- Have an active infection.
- Grade 3 or greater nephrocalcinosis as confirmed by renal ultrasound.

... and 31 more (see full listing online)

Locations (9 total)

University of California - San Francisco, San Francisco, California, United States
Yale Center for XLH/ Yale University School of Medicine, New Haven, Connecticut, United States
Indiana University School of Medicine University Hospital, Indianapolis, Indiana, United States
... and 6 more locations

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.